Additive Benefits of Pravastatin and Aspirin to Decrease Risks of Cardiovascular Disease
Charles H. Hennekens(Florida Atlantic University), René Belder(Bristol-Myers Squibb (Germany)), Scott Berry(Queen's University), Andrew Tonkin(Monash University), Bertram Pitt(Bayer (Germany)), Donald A. Berry(Berry & Associates (United States)), Chen Sheng-Lin(Bristol-Myers Squibb (Germany)), Andrew Walker(Bristol-Myers Squibb (Germany)), Robert P. Byington, Kannan Natarajan(Bristol-Myers Squibb (Germany)), Frederick T. Fiedorek(Bristol-Myers Squibb (Germany)), J. Wouter Jukema(Leiden University Medical Center), Neville F. Ford(Bristol-Myers Squibb (Germany)), Frank M. Sacks(Harvard University)
Cited by 111
Related Papers
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
REPRODUCIBILITY AND VALIDITY OF A SEMIQUANTITATIVE FOOD FREQUENCY QUESTIONNAIRE
|American Journal of Epidemiology|1985|4.3k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|Survey of Anesthesiology|2000|2.9k
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2020|2.6k